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Histo-blood group glycanNorovirus is a non-enveloped virus causing acute gastroenteritis. For human norovirus, no simple cell culture
system is available and consequently knowledge on cellular entry of the virus is limited. The virus binds to
ABH histo-blood group glycans on glycoproteins and glycosphingolipids. Non-secretors, characterized by the
lack of ABH histo-blood group glycans in the gastrointestinal tract, are resistant to most norovirus infections,
suggesting that these glycans may be part of the viral receptor. Recent studies have shown that polyomavirus
enters the cell via membrane invaginations induced by the multivalent binding of the virus to receptor
glycosphingolipids. In this study, we have investigated whether norovirus has the ability to induce membrane
invaginations on giant unilamellar vesicles (GUVs) containing puriﬁed glycosphingolipids. First, we character-
ized the glycosphingolipid binding pattern of VLPs from the Dijon strain (genogroup II.4), using thin-layer chro-
matography. The VLP recognized the ABH active glycosphingolipids H type 1, Lewis b, B type 1, A type 1 and A
Lewis b, but not lactotetraosylceramide or Lewis a, typically found in non-secretors. The binding pattern to
glycosphingolipids incorporated into GUVs was in full agreement with the thin-layer chromatography experi-
ments. Upon binding to the vesicles, the VLPs formed highly mobile clusters on the surface of the GUVs. VLP
containing tubular invaginations were seen on the GUVs containing glycosphingolipids recognized by the VLP.
In conclusion, this study suggests that humannorovirus has the ability to inducemembrane curvature by binding
to and clustering glycosphingolipids, which may reﬂect the ﬁrst step in cellular entry of the virus.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cell attachment and entry are essential steps of a virus infection [1].
The characterization of the host factors exploited by the virus for these
steps may provide targets for antiviral drugs directed against the host
instead of the pathogen [2]. For human norovirus, which causes the
winter vomiting disease, the knowledge of the entry process is limited
[3]. The study of this non-enveloped single stranded RNA virus has
been hampered by the lack of cell culture infectivity assays [4].
Many studies of human norovirus have made use of virus-like par-
ticles (VLPs), which are formed spontaneously when the recombinantartment of Infectious Diseases,
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l rights reserved.capsid protein is expressed in insect cells [5]. In vitro binding studies using
VLPs together with immobilized neoglycoproteins and saliva samples
have shown that the virus binds to glycans of the ABH histo-blood
group family in a strain dependentmanner [6]. For several strains, suscep-
tibility has been shown to correlate to host blood group status, suggesting
that ABH glycans may be part of the viral receptor [3]. Particularly,
so-called non-secretors have been identiﬁed as resistant to norovirus
infection [3]. Non-secretors constitute around 20% of the Caucasian
population and are characterized by a lack of expression of ABH glycans
on epithelial surfaces and in mucosal secretions. The non-secretor phe-
notype is caused by inactivating mutations in the fucosyltransferase 2
(FUT2) gene [7].
ABH glycans are found on glycoproteins and glycosphingolipids.
Human norovirus VLP has been shown to adhere to both [8–11]. To
our knowledge, no studies have so far addressed whether any of these
glycoconjugates may be functional receptors for the virus.
Recently, a mechanism for the function of the glycosphingolipid
Gb3 (Galα4Galβ4GlcCer) as receptor for the bacterial Shiga toxin was
1841G.E. Rydell et al. / Biochimica et Biophysica Acta 1828 (2013) 1840–1845described [12]. The multivalent binding of the toxin to the receptor
glycosphingolipidwas demonstrated to induce the formation of tubular
invaginations on the plasma membrane of the host cell. Interestingly,
the process could be reconstituted on giant unilamellar vesicles con-
taining 1,2-dioleoylphosphatidyl choline (DOPC), cholesterol, different
ceramide species of the glycosphingolipid Gb3 and a ﬂuorescent lipid,
included to visualize the membrane. Thus, tubule formation was an in-
trinsic property of the system and did not strictly require other cellular
factors [13,14]. The mechanisms by whichmembranes are bent are still
not clear, but likely involve line tension, asymmetric compressive stress,
a speciﬁc protein-lipid geometry, and the organization of lipids in
orientation ﬁelds [12,15]. Subsequently, themechanism has been ex-
tended to gangliosides as receptors for polyomaviruses and cholera
toxin [16,17].
In this study we have addressed the potential of glycosphingolipids
as receptors for human norovirus. The VLP studied belongs to the clini-
cally dominating genogroup GII.4 and shows a typical secretor gene
dependent binding pattern [18,19]. It has been shown to recognize
saliva samples from secretor individuals from all ABO blood groups
and Lewis genotypes [19]. Neoglycoprotein binding studies have demon-
strated speciﬁc binding of the VLP to α1,2-fucosylated glycans [19,20].
These studies also revealed a second binding speciﬁcity to sialylated
structures including SLex. In addition to ABH active glycans on salivary
glycoproteins, the VLP has been shown to recognize the H type 1 and
Leb epitopes on glycosphingolipids [10,11].
In the present studywe ﬁrst characterized the binding pattern of the
VLP to type 1 chain glycosphingolipids using a thin-layer chromatogram
binding assay. Thereafter, we incorporated glycosphingolipids into GUVs
and found that the Dijon VLP indeed has the ability to inducemembrane
invaginations upon binding to glycosphingolipids in a similar manner as
Shiga toxin and polyomaviruses [12,16].
2. Materials and methods
2.1. Glycosphingolipids
The glycosphingolipids were puriﬁed from human meconium sam-
ples pooled from individuals of the same ABO blood group or from
meconium of single individuals of known ABO blood groups [21]. The
individual glycosphingolipids were isolated by repeated silicic acid col-
umn chromatography of native nonacetylated and acetylated derivatives.
The identity and purity of the glycosphingolipids were all analyzed as
native structures by 1H NMR spectroscopy and compared to previous
characterizations by 1H NMR and mass spectrometric analyses of
permethylated and permethylated-reduced derivatives [9].
2.2. VLP
VLPs from the Dijon strain (Genbank no. AAL79839) were produced
by expressing the recombinant capsid protein in SF9 insect cells as
previously described [19,22]. The Dijon construct was a kind gift from
Dr. E. Kohli (University of Burgundi, Dijon, France). For the GUV assay
the VLPs were ﬂuorescently labeled using a Cy3 NHS ester (PA23001,
GE Healthcare, Sweden). One third of one labeling vial was dissolved
in phosphate buffer (0.1 M; pH 7.5) and 500 μg of VLP was added.
The reaction tube (V = 400 μl) was incubated 3.5 h at RT and then
over night at 4 °C. Thereafter theVLPsweredesalted in PBSona Sephadex
PD-10 column, ﬁnal volume, 750 μl. For stability reasons BSA, ﬁnal con-
centration 2 mg/ml, was added to the VLPs.
2.3. Antibodies
The mouse anti-Lewis a IgM antibody (Seraclone, LE1 clone 78 FR
2.3) was obtained from Biotest AG (Dreieich, Germany). The
ALP-conjugated anti-rabbit IgG was obtained from Sigma (St Louis,
MO). The Cy3-conjugated Donkey anti mouse antibody was obtainedfrom Beckman Coulter (Fullerton, CA). The norovirus antiserum
has been used previously in the chromatogram binding assay [10]
and was obtained by immunizing rabbits with puriﬁed VLP.
2.4. Chromatogram binding assay
The chromatogrambinding assaywas performed as described previ-
ously [10,23]. In brief, GSLswere applied to alumina-backed silica gel 60
HPTLC plates and chromatographed with chloroform:methanol:water
(60:35:8, by volume). The plate was then dried and cut into two parts.
One partwas chemically stained by sprayingwith anisaldehyde:sulfuric
acid:acetic acid (1:2:97 by volume) andheated at 180 °C. The other part
of the plate was plasticized with polyisobutylmethacrylate (P28, 0.3%)
in hexan:diethylether (1:1 by volume) and dried. The plastic-coated
plate was blocked in PBS with BSA and Tween-20 before being incubat-
ed with VLP. Antiserum against norovirus and a secondary alkaline
phosphatase conjugated antibody was used for detection of bound
VLPs.
2.5. Giant unilamellar vesicle assay
GUVs were grown by the electroformation technique essentially
as previously described [12,24]. The lipid composition was DOPC
(64 mol%), cholesterol (30 mol%), BodipyFL-C5-HPC (1 mol%, ﬂuo-
rescent green) and glycosphingolipids (5 mol%). The lipid mixtures
were dissolved in chloroform to a ﬁnal concentration of 0.5 mg/ml.
A 2 × 7.5 μl of lipid mixture was evaporated on conductive indium
tin oxide coated glass slides. The GUVs were grown in a sucrose solu-
tion adjusted to 300 mOsm in an alternating electric ﬁeld from 20 mV
to 1.1 V for 3 h. Thereafter 10 μl of GUV solutionwas added to 100 μl PBS
containing Cy3-labeled VLPs (20 μg/ml) or the anti Lewis a antibody
(diluted 1:20). The antibody was used together with a Cy3-conjugated
secondary antibody diluted 1:100. Fluorescence images of GUVs were
obtained at room temperature with a confocal microscope (A1R, Nikon,
Japan) equippedwith an oil immersion objective (60×, CFI Plan ApoVC).
3. Results and discussion
3.1. The VLP recognizes ABH active glycosphingolipids on thin-layer
chromatograms
The glycosphingolipid binding pattern of the Dijon VLP was de-
termined using a thin layer chromatogram binding assay. The struc-
tures, names and biosynthetic scheme of the glycosphingolipids used
are presented in Fig. 1. The VLPs recognized the α1,2-fucosylated
glycosphingolipids H type 1, Leb, A type 1, ALeb and B type 1 (Fig. 2).
The synthesis of these glycosphingolipids requires a functional secretor,
FUT2, gene and they are consequently not found in non-secretors. In con-
trast, the Lc4 or Lea glycosphingolipids typically found in non-secretors
were not recognized. A glycosphingolipid fraction originating from me-
conium of a single blood group B individual was also assayed for VLP
binding (Fig. 2). This fraction contains B type 1 and BLeb as major
fucosylated glycosphingolipid components [9,25]. The observed binding
to this fractionwas in agreementwith binding to H type 1, B type 1, BLeb
and long chain blood group B terminated glycosphingolipids. Control
plates were incubated with antibodies, but without VLP, to exclude the
possibility that the anti-VLP antibodies cross-reacted with any of the
glycosphingolipids. No binding was detected in this case. To conclude,
the VLP recognized α1,2-fucosylated type 1 chain glycosphingolipids
typically found in secretor blood group A, B, O and AB individuals.
Among secretors, Lewis (FUT3) genotype is not expected to determine
resistance to infection since structures both with the α1,4 linked fucose
(Leb and ALeb) and without it (H type 1, A type 1 and B type 1) were
recognized. The glycosphingolipid binding pattern observed was in
complete agreement with earlier binding studies assaying this VLP to-
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Fig. 1. Biosynthetic pathways for the synthesis of the histo-blood group ABH and Lewis type 1 chain glycosphingolipids. The secretor gene (FUT2) is underlined. The names of the
structures are; Lc4, lactotetraosylceramide; H type 1, H type 1 pentaglycosylceramide; Lea, Lewis a pentaglycosylceramide; A type 1, A type 1 hexaglycosylceramide; B type 1, B type
1 hexaglycosylceramide; Leb, Lewis b hexaglycosylceramide; ALeb, A Lewis b heptaglycosylceramide; and BLeb, B Lewis b heptaglycosylceramide.
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other GII.4 norovirus strains [3].3.2. The VLPs induce tubular invaginations upon binding to ABH active
glycosphingolipids in GUVs
To verify the glycosphingolipid binding pattern in a more biological
context and to investigatewhether theVLPhas the ability to inducemem-
brane invaginations upon glycosphingolipid binding, VLP binding to
glycosphingolipids in GUVs was tested. For these experiments, the VLP
was ﬂuorescently labeled with Cy3. In analogy with the thin-layer chro-
matogram binding assay experiments, the VLPs recognized GUVs
containing the α1,2-fucosylated glycosphingolipids H type 1, Leb, B type
1 and ALeb. Upon binding to the vesicles, the VLPs formed highly mobile
clusters on the surface of the GUVs. VLP containing tubular invaginations
were seen on the GUVs containing binding glycosphingolipids (Fig. 3,
Supplementary video). The invaginations contained both the ﬂuorescent
lipid, BodipyFL-C5-HPC, and the Cy3 labeled VLP. Since the GUVs were
only imaged in one plane it cannot be excluded that some of the clusters
were tubular invaginations pointing out of the imagedplane. TheVLPs did
not bind, nor induce invaginations on GUVs containing Lc4 or Lea. The in-
corporation of the Lea glycosphingolipid into the GUVs was conﬁrmed
using the monoclonal IgM antibody together with a ﬂuorescently labeledFig. 2. The norovirus VLP recognizes ABH active glycosphingolipids on thin-layer chromat
either stained for glycosphingolipids using anisaldehyde (right), or plasticized and incubate
tase (ALP) staining. The VLP recognized the secretor α1,2-fucosylated structures H type 1, Le
in non-secretors. The lane labeled Bmix contains partially puriﬁed meconium glycosphingo
that lane is in agreement with binding to H type 1, B type 1, BLeb and long chain blood grosecondary antibody (Fig. 4). The antibody bound uniformly to the vesicles
and did not induce any invaginations.
In summary, thebindingpatternsof theDijonVLP toglycosphingolipds
separated on thin layer chromatograms and included in lipid bilayers
are similar. TheVLPbinds to glycosphingolipids typically found in secre-
tors irrespective of ABO blood group and Lewis genotype. Upon binding
to glycosphingolipids in GUVs, the VLP has the ability to induce tubular
membrane invaginations.
3.3. The multivalent presentation of the binding sites on the VLP
Compared to Shiga toxin, cholera toxin and the SV40 virus [12,16],
a lower number of tubules per GUV was observed for the norovirus
VLP. This difference could be due to a difference in the localization of
the binding sites. The receptor binding domains of the Shiga toxin, chol-
era toxin and SV40 virus are all organized into pentameric structures.
For the two toxins, the B-subunit forms one single pentamer, whereas
the SV40 capsid contains 72 pentamers of the VP1 protein. Despite al-
most no amino acid sequence homology, the three pentameric struc-
tures are very similar. On each pentamer, ﬁve binding sites are located
with a distance of around 3 nm between them, even though the Shiga
toxin has two additional binding sites per monomer [26]. The norovirus
capsid has a T = 3 icosahedral symmetry formed from180 copies of the
capsid protein organized into 90 dimers [27]. The S-domain of theograms. Glycosphingolipids were chromatographed on thin-layer plates, which were
d with the VLP (left). Bound VLP was detected using antibodies and alkaline phospha-
b, A type 1, ALeb and B type 1, but not the Lc4 or Lea glycosphingolipids typically found
lipids from a secretor blood group B individual [25]. The binding pattern observed for
up B terminated glycosphingolipids, as indicated in the ﬁgure.
Fig. 3. The norovirus VLP induces tubular membrane invaginations upon binding to ABH active glycosphingolipids in GUVs. The VLP bound to and induced invaginations on GUVs
containing the α1,2-fucosylated glycosphingolipids H type 1, Leb, ALeb and B type 1. No VLP binding or invaginations were seen on the GUVs containing Lc4 or Lea. Scale bars: 2 μm.
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dimers extending from the shell in arch-like protrusions. Pentamers of the
capsid protein are formed around the ﬁve-fold axis, but the hexamer sur-
rounding the three-fold axis is a more abundant structure (Fig. 5). Thedistance between the binding sites on the P-dimer of the VA387 capsid
protein (99% homology to the Dijon strain) measures 2.4 nm [28]. By
mapping the VA387 binding site on the crystal structure of the Norwalk
VLP, based on sequence alignment (Fig. 5B), the distances between the
Fig. 4. The anti-Lea antibody recognizes Lea active GUVs but does not induce tubules on the vesicles. Scale bar: 2 μm.
1844 G.E. Rydell et al. / Biochimica et Biophysica Acta 1828 (2013) 1840–1845binding sites around the ﬁve- and three-fold symmetry axes may be esti-
mated to around 6.0 and 5.4 nm respectively (Fig. 5). This suggests that
the binding sites on the norovirus capsid are separated by longer
distances than the binding sites on the Shiga and cholera toxins as
well as the SV40 virus capsid. A recent study of the binding kinetics
between the Dijon VLP and small glycosphingolipid containing vesi-
cles (radius 20–220 nm) has suggested that the VLP bound to 6–12
glycosphingolipids [11]. Noteworthy, the energy cost to deform such
small vesicles is larger than the cost to deform the GUVs used in the
present study.
GUV studies with Shiga toxin have demonstrated that Gb3 species
with unsaturated ceramides are required for the formation of the
tubular membrane invaginations [12]. For SV40, studies with GM1
neoglycolipids suggested that the acyl chain length was a more impor-
tant factor for the tubule formation than the saturation degree [16]. TheFig. 5.A) The position of the GII.4 binding sitesmapped on the crystal structure of the GI.1
VLP (PDB ID: 1IHM). The three- and ﬁve-fold symmetry axes are indicated and the
distance between the binding sites in the different geometries is given. The amino acids
corresponding to the GII.4 VA387 fucose binding site (PDB ID: 2OBT) are shown as balls.
The image was constructed using the Chimera package [33]. B) Partial alignment of the
capsid protein of the Dijon strain, used in this study, and the VA387 (GII.4) and Norwalk
(GI.1) strains. The amino acids interactingwith theα1,2-fucose in the VA387 crystal struc-
ture are underlined. The corresponding amino acids of the Norwalk strain are in bold. The
numbering refers to the amino acids of the VA387 strain.glycosphingolipids used in this study are puriﬁed from humanmeconi-
um. The glycosphingolipids fractions are>95% pure concerning the gly-
cans, as determined by 1H NMR but each fraction contains a mixture of
ceramide species. The ceramide compositions have been determined by
MS and were dominated by phytosphingosine and sphingosine with a
series of hydroxylated C16:0–C24:0 fatty acids [21]. The fractions thus
contain relatively long chain structures. Minor amounts of unsaturated
ceramides were also detected. Importantly, the composition is similar
between the different fractions.
The demonstrated ability of norovirus to induce invaginations on
GUVs, in a similar manner as polyomaviruses and Shiga toxin, indicates
that glycosphingolipids may be cellular receptors for human norovirus.
Cell biology experiments are of course required to demonstrate the re-
ceptor function, but the formation of tubular invaginations is an initial
step for other pathogens using glycosphingolipids as receptors. For the
SV40 virus, the membrane invagination process was demonstrated to
be involved in the infectious entry pathway [16].
Murine norovirus, which causes a systemic disease quite different
from the gastroenteritis caused by human norovirus, has been suggested
to use gangliosides as receptors on macrophages [29]. Interestingly, the
entry of murine norovirus has been described to be independent of
caveolin and clathrin, but dependent of cholesterol [30,31]. These proper-
ties are characteristic also for the endocytosis of polyomaviruses and the
Shiga toxin [12,16]. An involvement of cholesterol in humannorovirus in-
fection has been suggested by the identiﬁcation of statin treatment as a
risk factor for severe norovirus infection [32]. However, cholesterol may
be involved in other steps of the virus infection than entry.
4. Conclusions
This study has demonstrated that a GII.4 human norovirus VLP recog-
nizes epithelial glycosphingolipids in a secretor gene (FUT2) dependent
manner. By binding to and clustering of glycosphingolipids incorporated
into GUVs, the VLP has the ability to induce negative membrane curva-
ture. This process may reﬂect the ﬁrst step in cellular entry of the virus.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamem.2013.03.016.
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